Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 11c ; offers Guidance

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $1.18, $0.11 better than the analyst estimate of $1.07. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $59.11 million.

GUIDANCE:

Eagle Pharmaceuticals sees Q3 2023 EPS of $4.40-$4.70, versus the consensus of $4.48.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Dutch Bros Inc. (BROS) PT Raised to $90 at DA Davidson on Sales/Earnings Upside
• AeroVironment restates quarterly financials, citing $89M goodwill error